TY - JOUR
T1 - Effects of a partially supervised conditioning program in cystic fibrosis
T2 - an international multicenter randomized controlled trial (ACTIVATE-CF)
AU - ACTIVATE-CF Study Working Group
AU - Hebestreit, Helge
AU - Kriemler, Susi
AU - Schindler, Christian
AU - Stein, Lothar
AU - Karila, Chantal
AU - Urquhart, Don
AU - Orenstein, David M.
AU - Lands, Larry C.
AU - Schaeff, Jonathan
AU - Eber, Ernst
AU - Radtke, Thomas
N1 - Funding Information:
Supported by the Mukovizisose e.V. (1402); the Swiss Society for Cystic Fibrosis; Cystic Fibrosis Canada; Vaincre la Mucoviscidose; Nederlandse Cystic Fibrosis Stichting; Edinburgh Children’s Hospital Charity; the Cystic Fibrosis Foundation (ORENST14K0); Stiftung Telethon Aktion Schweiz; Schweizerischer Nationalfonds zur Fo€rderung der Wissenschaftlichen Forschung (320030_144175); and Mylan Healthcare GmbH. The international coordination of the project was funded through a Vertex Innovation Award, which is an unconditional research grant provided by Vertex Pharmaceuticals (Vertex Innovation Award ACTIVATE-CF). The funding bodies had no role in the design of the study, data collection, or writing of this manuscript.
Publisher Copyright:
© 2022 by the American Thoracic Society
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Rationale: The long-term effects of vigorous physical activity (PA) on lung function in cystic fibrosis are unclear. Objectives: To evaluate effects of a 12-month partially supervised PA intervention using motivational feedback. Methods: In a parallel arm multicenter randomized controlled trial (ACTIVATE-CF), relatively inactive patients aged ≥12 years were randomly assigned (1:1 ratio) to an intervention group or control group. The intervention group consented to add 3 hours of vigorous PA per week, while the control group was asked not to change their PA behavior. Primary endpoint was change in percent predicted forced expiratory volume in 1s (ΔFEV1) at 6 months. Secondary endpoints included PA, exercise capacity, exercise motives, time to first exacerbation and exacerbation rates, quality of life, anxiety, depression, and stress, and blood glucose control. Data were analyzed using mixed linear models. Measurements and Main Results: 117 patients (40% of target sample size) were randomized to an intervention (n=60) or control group (n=57). After 6 months, ΔFEV1 was significantly higher in the control group compared to the intervention group (2.70% predicted, 95% CI 0.13 to 5.26; p=0.04). The intervention group reported increased vigorous PA compared with the control group at each study visit, had higher exercise capacity at 6 and 12 months, and higher PA at 12 months. No effects were seen in other secondary outcomes. Conclusions: ACTIVATE-CF increased vigorous PA and exercise capacity, with effects carried over for the subsequent 6 months, but resulted in better FEV1 in the control group.
AB - Rationale: The long-term effects of vigorous physical activity (PA) on lung function in cystic fibrosis are unclear. Objectives: To evaluate effects of a 12-month partially supervised PA intervention using motivational feedback. Methods: In a parallel arm multicenter randomized controlled trial (ACTIVATE-CF), relatively inactive patients aged ≥12 years were randomly assigned (1:1 ratio) to an intervention group or control group. The intervention group consented to add 3 hours of vigorous PA per week, while the control group was asked not to change their PA behavior. Primary endpoint was change in percent predicted forced expiratory volume in 1s (ΔFEV1) at 6 months. Secondary endpoints included PA, exercise capacity, exercise motives, time to first exacerbation and exacerbation rates, quality of life, anxiety, depression, and stress, and blood glucose control. Data were analyzed using mixed linear models. Measurements and Main Results: 117 patients (40% of target sample size) were randomized to an intervention (n=60) or control group (n=57). After 6 months, ΔFEV1 was significantly higher in the control group compared to the intervention group (2.70% predicted, 95% CI 0.13 to 5.26; p=0.04). The intervention group reported increased vigorous PA compared with the control group at each study visit, had higher exercise capacity at 6 and 12 months, and higher PA at 12 months. No effects were seen in other secondary outcomes. Conclusions: ACTIVATE-CF increased vigorous PA and exercise capacity, with effects carried over for the subsequent 6 months, but resulted in better FEV1 in the control group.
KW - cystic fibrosis
KW - exercise program
KW - physical activity
KW - exercise capacity
KW - randomized controlled trial
U2 - 10.1164/rccm.202106-1419OC
DO - 10.1164/rccm.202106-1419OC
M3 - Article
VL - 205
SP - 330
EP - 339
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
SN - 1073-449X
IS - 3
ER -